Saltar al contenido
Merck

SML2302

Sigma-Aldrich

Vildagliptin

≥98% (HPLC)

Sinónimos:

Vildagliptin, (2S)-1-[[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile, LAF-237, NVP-LAF237, (S)-1-(((1R,3R,5R,7S)-3-hydroxyadamantan-1-yl)glycyl)pyrrolidine-2-carbonitrile

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C17H25N3O2
Número de CAS:
Peso molecular:
303.40
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77

Ensayo

≥98% (HPLC)

Formulario

powder

actividad óptica

[α]/D -81 to -91°, c = 0.1 in methanol

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

N#C[C@H]1N(CCC1)C(CN[C@@](C[C@]2([H])C3)(C[C@@](C2)([H])C4)C[C@@]34O)=O

InChI

1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16+,17-/m0/s1

Clave InChI

SYOKIDBDQMKNDQ-NHMCJKAESA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

Vildagliptin has been used:
  • as a dipeptidyl peptidase-4 (DPP4) inhibitor to study its effects on endoplasmic reticulum (ER) pathway under diabetic conditions
  • in pharmacological inhibition to investigate the kinetics of transposable element (TE) desilencing and confirm its dependence on DPF-3 (a P-granule-localized N-terminal dipeptidase) enzymatic activity
  • to study its electrochemical properties and determination in biological fluid and drug forms

Acciones bioquímicas o fisiológicas

Vildagliptin ia a selective inhibitor of dipeptidyl peptidase 4 (DPP4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones that are released in response to a meal. By preventing GLP-1 and GIP inactivation, GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas.
Vildagliptin may participate in lipid metabolism. It plays a key role in attenuating postprandial hypertriglyceridemia, reducing serum triglycerides, apolipoprotein B, and blood total cholesterol levels. Vildagliptin is used in diabetes mellitus type 2 (DM2) therapy and may also possess vasculoprotective properties. Vildagliptin also helps to improve mitochondrial dysfunction caused by diabetes.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Roberto Trevisan
Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(6), 1215-1226 (2017-10-07)
Diabetes is the leading cause of chronic kidney disease, and even in the absence of albuminuria, decreased renal function in type 2 diabetes mellitus (T2DM) patients increases the risk for major adverse cardiovascular events and death. The evidence derived from
Pongpan Tanajak et al.
The Journal of endocrinology, 236(2), 69-84 (2017-11-17)
Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) effects on cardiac ischemia/reperfusion (I/R) injury are unclear. Unlike SGLT2-i, dipeptidyl peptidase 4 inhibitors (DPP4-i) have shown effective cardioprotection in cardiac I/R injury. We aimed to investigate whether SGLT2-i reduces myocardial dysfunction and myocardial injury
Rajani Kanth Gudipati et al.
Molecular cell, 81(11), 2388-2402 (2021-04-15)
Small RNA pathways defend the germlines of animals against selfish genetic elements, yet pathway activities need to be contained to prevent silencing of self genes. Here, we reveal a proteolytic mechanism that controls endogenous small interfering (22G) RNA activity in
Alberto Palazzuoli et al.
Heart failure reviews, 23(3), 325-335 (2018-01-24)
Heart failure (HF) is a common complication in patients with type 2 diabetes and it is closely associated with high morbidity and mortality rate. The incidence of cardiovascular events in patients with diabetes is related to high levels of glycemia
Michał Wiciński et al.
International journal of molecular sciences, 21(7) (2020-03-29)
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Glucagon-like peptide-1)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico